Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.

Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ

Open source

DOI: 10.1038/s41591-024-03267-1
Published: 2024 Dec
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03267-1,
  title = {Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.},
  author = {Shatsky RA and Trivedi MS and Yau C and Nanda R and Rugo HS and Davidian M and Tsiatis B and Wallace AM and Chien AJ and Stringer-Reasor E and Boughey JC and Omene C and Rozenblit M and Kalinsky K and Elias AD and Vaklavas C and Beckwith H and Williams N and Arora M and Nangia C and Roussos Torres ET and Thomas B and Albain KS and Clark AS and Falkson C and Hershman DL and Isaacs C and Thomas A and Tseng J and Sanford A and Yeung K and Boles S and Chen YY and Huppert L and Jahan N and Parker C and Giridhar K and Howard FM and Blackwood MM and Sanft T and Li W and Onishi N and Asare AL and Beineke P and Norwood P and Brown-Swigart L and Hirst GL and Matthews JB and Moore B and Symmans WF and Price E and Heditsian D and LeStage B and Perlmutter J and Pohlmann P and DeMichele A and Yee D and van 't Veer LJ and Hylton NM and Esserman LJ},
  year = {2024},
  journal = {Nature medicine},
  doi = {10.1038/s41591-024-03267-1},
  url = {https://doi.org/10.1038/s41591-024-03267-1}
}

RIS

TY  - JOUR
TI  - Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
AU  - Shatsky RA
AU  - Trivedi MS
AU  - Yau C
AU  - Nanda R
AU  - Rugo HS
AU  - Davidian M
AU  - Tsiatis B
AU  - Wallace AM
AU  - Chien AJ
AU  - Stringer-Reasor E
AU  - Boughey JC
AU  - Omene C
AU  - Rozenblit M
AU  - Kalinsky K
AU  - Elias AD
AU  - Vaklavas C
AU  - Beckwith H
AU  - Williams N
AU  - Arora M
AU  - Nangia C
AU  - Roussos Torres ET
AU  - Thomas B
AU  - Albain KS
AU  - Clark AS
AU  - Falkson C
AU  - Hershman DL
AU  - Isaacs C
AU  - Thomas A
AU  - Tseng J
AU  - Sanford A
AU  - Yeung K
AU  - Boles S
AU  - Chen YY
AU  - Huppert L
AU  - Jahan N
AU  - Parker C
AU  - Giridhar K
AU  - Howard FM
AU  - Blackwood MM
AU  - Sanft T
AU  - Li W
AU  - Onishi N
AU  - Asare AL
AU  - Beineke P
AU  - Norwood P
AU  - Brown-Swigart L
AU  - Hirst GL
AU  - Matthews JB
AU  - Moore B
AU  - Symmans WF
AU  - Price E
AU  - Heditsian D
AU  - LeStage B
AU  - Perlmutter J
AU  - Pohlmann P
AU  - DeMichele A
AU  - Yee D
AU  - van 't Veer LJ
AU  - Hylton NM
AU  - Esserman LJ
PY  - 2024
JO  - Nature medicine
DO  - 10.1038/s41591-024-03267-1
UR  - https://doi.org/10.1038/s41591-024-03267-1
ER  -

APA

RA, S., MS, T., C, Y., R, N., HS, R., M, D., B, T., AM, W., AJ, C., E, S., JC, B., C, O., M, R., K, K., AD, E., C, V., H, B., N, W., M, A., C, N., ET, R. T., B, T., KS, A., AS, C., C, F., DL, H., C, I., A, T., J, T., A, S., K, Y., S, B., YY, C., L, H., N, J., C, P., K, G., FM, H., MM, B., T, S., W, L., N, O., AL, A., P, B., P, N., L, B., GL, H., JB, M., B, M., WF, S., E, P., D, H., B, L., J, P., P, P., A, D., D, Y., LJ, V. '. V., NM, H., & LJ, E. (2024). Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.. Nature medicine. https://doi.org/10.1038/s41591-024-03267-1

Source records

pubmed · retrieved 2026-09-26T15:15:44.329Z